BioDelivery Sciences International Inc.
BDSI
NGS
Sector: Healthcare
Industry: Biotechnology
5.60
USD
0.00
(0.00%)
Optionable: Yes Market Cap: 575 M 90-day average vol: 5,852,158
Previous close: 5.58 Open: 5.58 Bid: Ask:
52 week range
2.50 5.62
Last updated: Saturday 14th May 2022
Valuation
Price per Sales TTM ($) | 3.45 |
Price per Book TTM ($) | 3.06 |
PE Ratio (TTM) | 6.70 |
Book Value per Share ($) | 1.82 |
5 Year PE Range-35.5 |
Returns
7 Day Return | 0.00% | |
1 Month Return | 0.00% | |
3 Month Return | 0.63% | |
1 Year Return | 75.94% | |
3 Year Return | 14.18% | |
5 Year Return | 179.75% | |
YTD Return | 80.48% |
Risk
Financial Health
Technicals
RSI (14 Day) | 83.90 |
14 Day SMA ($) | 5.58 |
14 Day EMA ($) | 5.52 |
Money Flow Index | 33.34 |
Average True Range | 0.07 |
50 Day SMA ($) | 4.51 |
200 Day SMA ($) | 3.80 |
ADX | 27.38 |
MACD | 0.28 |
Growth
Free Cash Flow QoQ Growth | 97.47% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 814.29% |
Revenue QoQ Growth | 5.02% |
EPS YoY Growth | 0.00% |
Profitability
Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline
Yahoo Finance 3/2/2022
Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?
Yahoo Finance 3/2/2022
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance 2/28/2022
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance 2/25/2022
BioDelivery Sciences launches migraine therapy in U.S.
Seeking Alpha 2/24/2022
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?
Yahoo Finance 2/24/2022
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
Yahoo Finance 2/24/2022
What to Expect From Precision BioSciences (DTIL) Q4 Earnings
Yahoo Finance 2/22/2022
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More
Yahoo Finance 2/16/2022
BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium
Yahoo Finance 2/15/2022
BioDelivery Sciences Buyout Is Good, Not Great
Seeking Alpha 2/15/2022
BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today
Yahoo Finance 2/14/2022
Raleigh drugmaker being acquired by competitor in $604M deal
Yahoo Finance 2/14/2022
Opioid maker Collegium buys N.C. competitor for $604M
Yahoo Finance 2/14/2022
Merger Mania Is Sending These 2 Little-Known Stocks Soaring
Yahoo Finance 2/14/2022
| NA |
|---|
| could not broadcast input array from shape (20) into shape (0) |
|---|
BDSI Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 55 M | 11 M | 39 M | 48 M | 16 M | 62 M | 56 M | 111 M | 156 M |
| Cost of sales | 423000 | 735000 | 4 M | 7 M | 10 M | 13 M | 10 M | 13 M | 17 M |
| Gross operating profit | 53 M | 9 M | 34 M | 40 M | 4 M | 42 M | 40 M | 90 M | 132 M |
| Selling Gen & administrative expense | 10 M | 12 M | 38 M | 55 M | 49 M | 59 M | 59 M | 86 M | 99 M |
| Research & development expense | 35 M | 53 M | 34 M | 21 M | 19 M | 13 M | 5 M | 0 | 0 |
| Operating income | 7 M | -56 M | -39 M | -35 M | -64 M | -29 M | -24 M | 4 M | 33 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -6 M | -89000 | -13 M | 25000 | 64000 | 27 M | -14000 | 4000 | -3000 |
| Pre-tax Income (EBT) | 2 M | -57 M | -54 M | -38 M | -67 M | -11 M | -34 M | -15 M | 26 M |
| Income taxes | 129000 | 0 | 0 | 0 | 0 | -16 M | 13000 | 5000 | 252000 |
| Net income from total operations | 2 M | -57 M | -54 M | -38 M | -67 M | 5 M | -34 M | -15 M | 26 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 2 M | -57 M | -54 M | -38 M | -67 M | 5 M | -34 M | -15 M | 26 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 2 M | -57 M | -54 M | -38 M | -67 M | 5 M | -34 M | -15 M | 26 M |
| Depreciation | 1 M | 1 M | 1 M | 1 M | 1 M | 6 M | 6 M | 9 M | 8 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | 3 M | -55 M | -51 M | -34 M | -62 M | 4 M | -18 M | 13 M | 40 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0.05 | -1.51 | -1.12 | -0.72 | -1.25 | 0.1 | -0.73 | -0.18 | 0.26 |
| Diluted EPS total | 0.05 | -1.51 | -1.12 | -0.72 | -1.25 | 0.09 | -0.73 | -0.18 | 0.24 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!